CME

This activity is supported by an educational grant from Incyte Corporation.

Expert Update: What's New in Essential Thrombocythemia

Expert Update: What's New in Essential Thrombocythemia

This activity is supported by an educational grant from Incyte Corporation.

Overview

Author(s)/Faculty: Srdan Verstovsek, MD, PhD
Source: Healio - Hematology/Oncology Education Lab
Type: VideoArticles/Items: 2
Release Date: 8/23/2017Expiration Date: 8/22/2018
Credit Type: CMENumber of Credits: 0.5
Cost: FreeProvider: Vindico Medical Education
Appropriate early diagnosis and initiation of therapy is essential in the management of myeloproliferative neoplasms (MPNs) to enhance clinical outcomes and patient quality of life. Recent revisions in the classification of myeloid neoplasms and acute leukemia by the World Health Organization have further defined criteria for the differential diagnosis of MPNs, including criteria for the discernment of essential thrombocythemia (ET) and prefibrotic/early primary myelofibrosis. However, many challenges remain in the management of patients with ET, especially regarding control of symptom burden, prediction of thrombosis risk, and management of those who are refractory to or resistant to first-line therapies. Ongoing clinical evaluation of second-line therapies that target JAK2 demonstrate the potential to improve symptom burden and quality of life of patients with ET. In this activity, Dr. Srdan Verstovsek provides expert review and evaluation of criteria for the differential diagnosis of ET, models to predict thrombosis, assessment of current and emerging treatment strategies, and guidance for the optimal management of patients with ET. 

CME Information

page 1 of 5